Study Background and Objectives

The Phase 4 CaboCombo (NCT05361434) clinical trial, led by Ipsen, was designed to evaluate the real-world efficacy and safety of cabozantinib (Cabometyx) and nivolumab (Opdivo) combination therapy in patients with advanced Renal Cell Carcinoma (aRCC). While the previous Phase 3 CheckMate-9ER trial was conducted in a strictly controlled environment, this Phase 4 trial aimed to validate the practical utility of the treatment by including patients with various comorbidities from real-world clinical settings. This reflects the market's demand to confirm whether the efficacy and clinical benefits observed in the treatment are consistent with patients' adherence in actual prescription settings.

Key Efficacy Data and Analysis

According to the final results analyzing 308 patients who were assessed for efficacy, the real-world Overall Survival (rwOS) at 18 months after treatment initiation was 74%, and the median real-world Progression-Free Survival (rwPFS) was 14.0 months. This demonstrates that the efficacy observed in the controlled Phase 3 trial can be reproduced in a heterogeneous patient population in real-world clinical settings, which is very encouraging data. This provides clinicians with objective evidence to actively recommend the combination therapy to patients who may have hesitated to receive treatment due to not meeting the clinical trial criteria.

Safety and Patient Convenience

In terms of safety, no new safety signals were observed beyond those reported in the previous CheckMate-9ER study, and adverse events were manageable within expected ranges. Confirming that the rate of early treatment discontinuation or dose reduction due to drug-related adverse events is within a realistic management framework can contribute to improving adherence in patients undergoing long-term treatment. The fact that manageable toxicity is possible in real-world clinical settings when using a combination of a Tyrosine Kinase Inhibitor (TKI) and an Immune Checkpoint Inhibitor (ICI) is a significant factor in reducing the barriers to prescribing this therapy.

Market Competition and Significance

The global market for first-line treatment of advanced RCC is estimated at approximately $7.0 billion to $7.4 billion in 2025, with strong competitors such as the Keytruda (Pembrolizumab) and Lenvatinib combination therapy from MSD and Eisai. In this highly competitive landscape, the real-world data obtained by Ipsen's Cabometyx and BMS's Opdivo combination therapy will be a key asset in securing a competitive advantage in drug bidding and negotiations for reimbursement coverage in various countries. In reality, countries or insurance companies with limited healthcare budgets place more importance on cost-effectiveness based on real-world prescription data rather than controlled clinical trials, which is expected to have a positive impact on market share expansion.

License Agreements and Future Prospects

In 2016, Ipsen entered into an exclusive license agreement with Exelixis for a total of $855 million, including an upfront payment of $200 million and milestone payments of up to $655 million, to acquire the rights to cabozantinib in the United States, Canada, and Japan, as well as other regions. The acquisition of this real-world data will further enhance Ipsen's marketing competitiveness, maximize royalty revenue from licensed territories, and provide a strong clinical basis for supporting additional indications. In the future, this combination therapy is expected to solidify its position as a global standard of care based on the synergy between a multi-TKI that targets VEGFR 1/2/3, MET, and AXL and a PD-1 immune checkpoint inhibitor.